EUCTR2022-000074-25-IT进行中（未招募）1 期
A PHASE III, OPEN LABEL, SINGLE ARM, MULTI-CENTER, TRIAL TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION HETERODIMER CANDIDATE (PHH-1V) AGAINST SARS-COV-2, IN ADULTS VACCINATED AGAINST COVID-19 -
HIPRA SCIENTIFIC S.L.0 个研究点目标入组 3,000 人开始时间: 2022年3月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male or female, =16 years old at Day 0.
- •-Willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures.
- •-Have a recognized primary vaccination scheme recognized by the authorities with Comirnaty, Spikevax, Vaxevria or Janssen at least 91 days and preferably a maximum of 240 days before Day 0.
- •-Participants may have underlying illnesses if are stable and well-controlled according to the investigator judgment.
- •-Participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine.
- •-Participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination.
- •-Female participants of childbearing potential must have a negative pregnancy test on the on Day 0 prior to vaccination.
- •-Female participants of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom).
- •-Male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence).
- •-Male participants must refrain from donating sperm for at least 28 days after day 0.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2940
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •-History of anaphylaxis to any prior vaccine.
- •-Previous severe SARS-CoV-2 infections are not permitted (ote: Severity explained as any episode of COVID-19 requiring = 24hrs of hospitalization).
- •-Participant received or plans to receive live attenuated vaccines within 4 weeks before and after day 0; or other not live vaccines within 14 days before and after day 0.
- •-Pregnancy or breast-feeding at screening or Day 0 or willingness/intention to become pregnant during the study.
- •-Participant has a clinically significant acute illness or fever (temperature =38º C (100.4ºF)) at screening or within 48 hours prior to Day 0.
- •-Participant had a surgery requiring hospitalization before vaccination and he/she has not received the hospital discharge at day 0; or has a surgery requiring hospitalization planned within 12 weeks after study vaccine administration.
- •-Participant has any active malignancy even if under treatment except for non-melanoma skin cancer, uterine cervical carcinoma, anal carcinoma, localized prostate cancer.
- •-Participant has ongoing severe and non-stable psychiatric condition likely to affect participation in the study.
- •-Participant has a problematic or risk use of substances including alcohol that can compromise the study follow-up.
- •-Participant has a bleeding disorder or has any condition that in the opinion of the investigator contraindicates intramuscular injections.
- •-Participant has abnormal function of the immune system, except stable clinical conditions like controlled HIV.
- •-Participants have clinically significant and unstable cardiovascular, respiratory, hepatic, neurological, gastrointestinal, renal, or any other medical disorder judged by the investigator clinically significant and unstable within 3 months before screening.
- •-Chronic or recurrent administration of systemic immunosuppressant medication.
- •-Subject has received immunoglobulins and/or blood-derived products 12 weeks prior vaccination (Day 0) or expects to receive them during the study.
- •-Participant received any immunotherapy (monoclonal antibodies, plasma) aimed to prevent or treat COVID-19 within 90 days before day 0.
- •-Participation in any research involving an investigational product (drug, biologic, device) within 12 weeks prior to vaccination and during the study.
- •-Participant has donated = 450ml of blood products within 12 weeks before screening.
- •-Participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.
研究者
相似试验
进行中（未招募）
1 期
A large, international study in advanced wild-type melanoma looking at the efficacy and safety with cobimetinib (targeted therapy) plus atezolizumab (immunotherapy) compared to pembrolizumab (immunotherapy) where the assigned drug therapy will be known by the patient and investigator.Metastatic BRAFV600 wild-type melanomaMedDRA version: 20.0Level: PTClassification code 10040808Term: Skin cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004387-18-ITF. HOFFMANN - LA ROCHE LTD.446
进行中（未招募）
1 期
A Study to Look at the Efficacy and Safety of Cobimetinib Plus Atezolizumab vs. Pembrolizumab in Patients with Previously Untreated Advanced Skin CancerEUCTR2016-004387-18-GBF. Hoffman-La Roche Ltd.450
进行中（未招募）
1 期
A Study to Look at the Efficacy and Safety of Cobimetinib Plus Atezolizumab vs. Pembrolizumab in Patients with Previously Untreated Advanced Skin CancerMetastatic BRAFV600 wild-type melanomaMedDRA version: 20.0Level: PTClassification code 10040808Term: Skin cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004387-18-BEF. Hoffman-La Roche Ltd.446
进行中（未招募）
1 期
A Study to Look at the Efficacy and Safety of Cobimetinib Plus Atezolizumab vs. Pembrolizumab in Patients with Previously Untreated Advanced Skin CancerMetastatic BRAFV600 wild-type melanomaMedDRA version: 20.0Level: PTClassification code 10040808Term: Skin cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004387-18-PLF. Hoffman-La Roche Ltd.446
进行中（未招募）
1 期
A Study to Look at the Efficacy and Safety of Cobimetinib Plus Atezolizumab vs. Pembrolizumab in Patients with Previously Untreated Advanced Skin CancerMetastatic BRAFV600 wild-type melanomaMedDRA version: 20.0Level: PTClassification code 10040808Term: Skin cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004387-18-HUF. Hoffman-La Roche Ltd.446